Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease and Search Prognosis

Allogeneic hematopoietic cell transplantation (alloHCT) is potentially curative for hematologic malignancies and non-malignant disorders including inherited metabolic disorders, hemoglobinopathies and bone marrow failure syndromes. The optimal donor for alloHCT is an HLA identical sibling. Unfortunately, approximately 70% of patients in need of alloHCT will not have a fully matched donor in their family and must pursue an unrelated adult donor (URD), umbilical cord blood (UCB) or a mismatched related donor as a graft source.

Source: Biology of Blood and Marrow Transplantation - October 9, 2020 Category: Hematology Authors: Jason Dehn, Pintip Chitphakdithai, Bronwen E. Shaw, Abby A. McDonald, Steven M. Devine, Linda J. Burns, Stephen Spellman Source Type: research